Clinical Trials Sponsored by Mytrus

Total 2818 results

Bristol-Myers Squibb

Withdrawn

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)

Non-Small Cell Lung Cancer

Argentina, Peru, Germany, United States, Canada
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
Bristol-Myers Squibb

Completed

An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism Study in Healthy Male Participants

Cancer

United States
Bristol-Myers Squibb

Completed

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Multiple Myeloma

United States, Spain
Bristol-Myers Squibb

Completed

Eliquis Regulatory Post Marketing Surveillance

NonValvular Atrial Fibrillation

Korea, Republic of
Bristol-Myers Squibb

Completed

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

Psoriasis

Australia
Bristol-Myers Squibb

Completed

Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study (PASS)

Leukemia
Bristol-Myers Squibb

Withdrawn

Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

Renal Cell Carcinoma

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Giant Cell Arteritis

Poland, United States, Spain, France, Austria, Belgium, Italy, Romania, Switzerland, Germany, Greece, Netherlands, Australia, Denmark, United Kingdom, Ireland, Bulgaria, Canada, Estonia, Serbia, Sweden
Bristol-Myers Squibb

Completed

A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects

Thrombosis

United States
Bristol-Myers Squibb

Completed

Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

Deep Vein Thrombosis | Pulmonary Embolism

Mexico
Bristol-Myers Squibb

Completed

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

Heart Decompensation, Acute

United States
Bristol-Myers Squibb

Completed

A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection

Hepatitis C

China, Korea, Republic of, Russian Federation
Bristol-Myers Squibb

Completed

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Head and Neck Cancer | Colorectal Cancer

United States
Bristol-Myers Squibb

Completed

Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France

Anticoagulation

France
Bristol-Myers Squibb

Completed

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Thrombosis

United States
Bristol-Myers Squibb

Terminated

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Multiple Myeloma

United States, Italy, France, Spain
Bristol-Myers Squibb

Completed

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant (ALLY 1)

Hepatitis C

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Hepatitis C

France, Australia
Bristol-Myers Squibb

Completed

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis

United States, Portugal, Italy, Brazil, Germany, Peru, France, Spain, Mexico, Austria, Switzerland
Bristol-Myers Squibb

Completed

An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy

Rheumatoid Arthritis

United Kingdom
Bristol-Myers Squibb

Completed

A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids

Renal Transplant

Argentina, Australia, India, United States, Belgium, Brazil, Poland, Mexico, Canada, France, Germany, Spain
Bristol-Myers Squibb

Completed

Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

Healthy Subjects

Australia
Bristol-Myers Squibb

Completed

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

Arthritis

United States
Bristol-Myers Squibb

Completed

Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Chronic Phase Chronic Myeloid Leukemia

France, Italy, United States, Korea, Republic of, Germany
Bristol-Myers Squibb

Completed

Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants

Venous Thromboembolism

United States
Motus Therapeutics, Inc.

Completed

Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa

Anorexia Nervosa

United States
Motus Therapeutics, Inc.

Completed

Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis

Gastroparesis | Gastrointestinal Motility Disorder | Diabetes Mellitus Complications | Diabetes Mellitus Type 1 and 2

United States
Bristol-Myers Squibb

Completed

A Study of the Alternative Administration of Ixabepilone and Vinflunine

Cancer

United States
Bristol-Myers Squibb

Completed

Effect of Ketoconazole on the Pharmacokinetics of Vinflunine

Cancer

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Completed

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects (INH-189-006)

Hepatitis C

United States, Puerto Rico
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

United States, Canada
Bristol-Myers Squibb

Completed

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Leukemia

United States, Canada, Finland, Italy, United Kingdom, France, Germany
Bristol-Myers Squibb

Completed

Interferon Toxicities in Melanoma Treatment (ITMT)

Stage III Melanoma
Bristol-Myers Squibb

Completed

Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

Atrial Fibrillation
Bristol-Myers Squibb

Completed

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Hepatitis C Virus Infection

Australia, France, Germany, Korea, Republic of, Sweden, Taiwan, United Kingdom, United States, Canada, Mexico, Austria, Italy, Spain, Denmark, Argentina, Poland, Ireland, Greece, New Zealand
Bristol-Myers Squibb

Completed

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Advanced Breast Cancer

United States
Bristol-Myers Squibb

Completed

Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden

Anticoagulation
Bristol-Myers Squibb

Terminated

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Healthy Adult Volunteers

United States
Bristol-Myers Squibb

Completed

Korean Post-marketing Surveillance for Orencia®

Rheumatoid Arthritis

Korea, Republic of
Bristol-Myers Squibb

Completed

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

Atrial Fibrillation
Bristol-Myers Squibb

Completed

Korean Post-marketing Surveillance for Sprycel®

Leukemia, Myelomonocytic, Chronic | Leukemia-Lymphoma

Korea, Republic of
Bristol-Myers Squibb

Completed

Eliquis Regulatory Post Marketing Surveillance (rPMS)

Venous Thromboembolism

Korea, Republic of
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Hepatitis C, Genotype 1

United States, Australia, France, Germany, Spain, Canada, Puerto Rico, Argentina, Brazil, Russian Federation, United Kingdom, Italy, Belgium
Bristol-Myers Squibb

No longer available

EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

Chronic Hepatitis C

Netherlands, Austria, Germany, United Kingdom, Sweden
Bristol-Myers Squibb

Completed

Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)

Venous Thromboembolism

3

Subscribe